PURPOSE: Intra-operative intertitial brachytherapy has been applied in the curative and palliative treatment of @entity2 . Implantation of radio-active sources offers an advantage over external irradiation because of the limited penetrability from source to prescription point, resulting in rapid dose fall-off and sparing of surrounding normal tissues. The aim of this study was to re-evaluate retrospectively the Antoine-Lacassagne @entity5 center experience in endobronchial brachytherapy by low dose rate (LDR) or @entity1168 ( @entity1168 ) and to design perspectives for the next decades. Evaluation was based on analysis of @entity137 , response rates and survival. MATERIALS AND METHODS: From october 1989 to june 1999, 31 consecutive @entity1 with @entity153 were treated. Thirteen and 18 @entity1 received LDR and @entity1168 , respectively. The mean age was 65 years (range 44 to 79 years). Inclusion criteria were, for palliative treatment, incurable @entity5 , and for curative treatment, @entity41 in the margins after resection, or @entity5 could not be treated surgically. Exclusion criteria were sites of lesion unsuitable for placement of the brachytherapy catheter. Evaluation of complications and clinical response were based on endoscopic evaluation one month after the last session and at less one year after the end of treatment. RESULTS: Eighty-seven courses have been performed: 65 by LDR and 22 by @entity1168 . Thirty-six courses have been performed in the palliative group, 51 courses in the curative group. Seven @entity1 among 31 presented acute complications and 18/31 late complications. Complete global response rate was 14/30 evaluable @entity1 (47%). Mean overall global survival was 23 months with a median follow-up of 3.5 years. CONCLUSION: These results confirm the efficacy of endobronchial brachytherapy as well as palliative or curative treatment, but the improvement of results will essentially depend on our capacity to better define our indications and underlie the necessity to perform phase III international randomised trial.

[Reappraisal of the role of endobronchial brachytherapy in the management of XXXX : ten years' experience at the centre Antoine-Lacassagne].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'endobronchial tumor', 'endobronchial cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity153 :: ('MESH:D002283', 'Disease') :: ['bronchogenic carcinoma'] @entity1168 :: ('MESH:D001919', 'Disease') :: ['HDR', 'high dose rate']
@entity2 :: (MESH:D008175,Disease) :: ['lung cancer']
